Mesoporous Hydroxyapatite Nanoparticle as Antidepressant Drug Carrier
Date Issued
2010
Date
2010
Author(s)
Chen, Cheng
Abstract
Depression is becoming a dangerous threat among us nowadays, and it is a major concern that cannot be neglected. Currently, there is no sure way to prevent depression. Hence, it is essential to have a reliable medication at earlier stages to prevent depression from worsening and reoccurrence of symptoms.
In this thesis report, we propose the use of mesoporous hydroxapatite (HAP) nanoparticle as a long-lasting antidepressant drug carrier for its unique attribute in biodegradability. HAP nanoparticles synthesized are surface-modified by acrylic acid (AA) and linoleic acid (LA) for various purposes. The surface-modified HAP nanoparticles are then loaded with the latest generation of antidepressant, olanzapine (Zyprexa®, OLZ). The results have indicated a steady release of drug in in vitro experiments for a 7-week period. Lastly, the relative low cytotoxicity of HAP-AA-LA-OLZ nanoparticles is proven by LDH, and WST-1 shows there is no negative effect on cell viability and cell proliferation in in vitro studies. This study is the first to report the use of hydroxyapatite as a mesoporous nanoparticle drug carrier.
Subjects
hydroxyapatite
mesoporous nanoparticles
biodegradability
acrylic acid
linoleic acid
antidepressant
Type
thesis
File(s)![Thumbnail Image]()
Loading...
Name
ntu-99-R97548055-1.pdf
Size
23.53 KB
Format
Adobe PDF
Checksum
(MD5):d51ec04d50a5880ed65892a4add960dc